Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group.
暂无分享，去创建一个
M. Narabayashi | Y. Kagami | M. Ogura | T. Kinoshita | K. Tobinai | Y. Sasaki | Y. Morishima | T. Igarashi | T. Ohtsu | Y. Kobayashi | Y. Kagami | T. Murate | Michinori Ogura | Yasuo Morishima | Takashi Murate | Yukio Kobayashi | Masaru Narabayashi | Tomohiro Kinoshita | M. Ogura